Please assess the completion status of the following clinical trial:

Trial Title: Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~This protocol is open to male and female patients of all races with a diagnosis of severe sickle hemoglobinopathy providing they also satisfy the following eligibility criteria:~* Adult and pediatric patients with Hb SC disease who are able to swallow the Mg pidolate preparation and who have had at least one prior painful crisis.~Exclusion Criteria:~* Patients transfused within 90 days of study entry,~* Patients with elevated (\>1.5 times upper limit of normal for age) BUN, creatinine, or liver function tests \> 3 times the upper limit of normal for age,~* Patients who take a magnesium-containing medication (Mylanta, Maalox, etc.) on a regular (i.e., more than 2 days per week) basis.~* Patients with progressive neuromuscular disease or patients who are treated with a calcium channel blocker.~* Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment.
- MG Pidolate Administration (Type: ACTIVE_COMPARATOR): A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).